BC Extra | Dec 5, 2017
Financial News

Heron raises $150M in follow-on

Heron Therapeutics Inc. (NASDAQ:HRTX) raised $150 million in a follow-on underwritten by Cantor Fitzgerald. The company markets Sustol granisetron extended release (APF530) to prevent chemotherapy-induced nausea and vomiting (CINV). The product is a long-acting formulation...
BC Innovations | Nov 6, 2017
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest endosome-targeting conjugates of CRLR and NK1R antagonists could help treat chronic pain. The conjugates were created by linking CRLR and NK1R antagonist tool compounds to the lipid cholestanol, which targets...
BC Innovations | Jul 13, 2017
Targets & Mechanisms

Insider signaling

With evidence mounting that cell surface receptors keep signaling after they are internalized, a Takeda-backed study from Monash University has shown how the phenomenon could solve the riddle of why antagonists of the substance P...
BC Innovations | May 9, 2017
Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Mouse and cell culture studies suggest inhibiting TACR1 or agonizing TRPV1 could help prevent pancreatic intraepithelial neoplasms (PanINs) from progressing to pancreatic ductal adenocarcinoma (PDAC). In a mouse model of PDAC, axon...
BC Extra | Jan 19, 2017
Financial News

Heron raises $150M in follow-on

Heron Therapeutics Inc. (NASDAQ:HRTX) raised $150 million through the sale of 12.3 million shares at $12.20 in a follow-on underwritten by BofA Merrill Lynch, Cowen, Leerink, Cantor Fitzgerald, JMP Securities, Noble Capital Markets, LifeSci Capital,...
BC Week In Review | Jan 12, 2017
Clinical News

Cinvanti regulatory update

Heron submitted an NDA to FDA for IV Cinvanti to prevent chemotherapy-induced nausea and vomiting (CINV). The company expects a decision in late 2017. Cinvanti is a polysorbate 80-free formulation of aprepitant, a tachykinin receptor...
BC Week In Review | Apr 4, 2016
Clinical News

Emend regulatory update

Japan approved a regulatory application from Ono for IV Proemend fosaprepitant meglumine to include treatment of chemotherapy-induced nausea and vomiting (CINV) in pediatric patients ages >=6 months. The injectable formulation of the selective neurokinin 1...
BioCentury | Jan 11, 2016
Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BC Week In Review | Nov 2, 2015
Clinical News

Emend regulatory update

EMA’s CHMP recommended approval of a label expansion for Emend from Merck to include patients ages >=6 months. The injectable formulation of a selective neurokinin 1 (NK1) receptor antagonist is approved in the EU to...
BC Week In Review | Sep 14, 2015
Clinical News

Emend aprepitant regulatory update

FDA approved an sNDA from Merck for Emend aprepitant to prevent chemotherapy-induced nausea and vomiting (CINV) in combination with other antiemetics in patients ages <12 who weigh >=30 kg and pediatric patients ages >=12. Specifically,...
Items per page:
1 - 10 of 61